文献速递帕金森病与运动障碍

抗体诱导的肉毒神经毒素治疗继发性失效的频率与危险因素

Frequency and risk factors of antibody-induced secondary failure of botulinum neurotoxin therapy.
PubMed 文献 · Neurology · 2020-04-24

这项单中心回顾性队列研究分析了1995至2015年启动肉毒神经毒素(BoNT)治疗的471例神经系统适应症患者,其中173例通过小鼠半膈肌试验检测中和抗体(NAB)。

要点

  • 每次治疗高剂量、剂型间转换(至incobotulinumtoxinA除外)及颈部肌肉治疗为独立危险因素。
  • 仅使用incobotulinumtoxinA的49例患者中无一发生NAB-cSTF。

核心结论

  • 各种适应症和BoNT剂型下NAB-cSTF总体风险较低,但应使用尽可能低的剂量并避免不必要的剂型转换。

研究设计与样本

  • 单中心回顾性队列研究,纳入1995至2015年间启动BoNT治疗的471例患者,其中173例(93例疑似治疗失败,80例前瞻性研究参与者)通过小鼠半膈肌试验检测NAB。

主要发现

  • 治疗 duration 为9.8±6.2年(范围0.5-30年),依从性70.6%,治疗周期数为31.2±22.5(范围3-112)。
  • 仅使用incobotulinumtoxinA的49例患者治疗8.4±4.2年(范围1-14年)期间无一发生NAB-cSTF。
  • 独立危险因素为每次治疗高BoNT剂量、在onabotulinumtoxinA与其他BoNT剂型间转换(转换至incobotulinumtoxinA除外)以及颈部肌肉治疗。

临床怎么用

  • 在颈部肌张力障碍等适应症中尤其应使用尽可能低的BoNT剂量以降低NAB-cSTF风险。
  • 避免不必要的BoNT剂型间转换,转换至incobotulinumtoxinA可能不增加风险。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To investigate the risk factors of neutralizing antibody (NAB)-induced complete secondary treatment failure (cSTF) during long-term botulinum neurotoxin (BoNT) treatment in various neurologic indications. METHODS: This monocenter retrospective cohort study analyzed the data of 471 patients started on BoNT therapy between 1995 and 2015. Blood samples of 173 patients were investigated for NABs using the mouse hemidiaphragm test (93 with suspected therapy failure, 80 prospective study participants). The frequency of NAB-cSTF was assessed for various indications: hemifacial spasm, blepharospasm, cervical dystonia, other dystonia, and spasticity. A priori defined potential risk factors for NAB-cSTF were evaluated, and a stepwise binary logistic regression analysis was performed to identify independent risk factors. RESULTS: Treatment duration was 9.8 ± 6.2 years (range, 0.5-30 years; adherence, 70.6%) and number of treatment cycles 31.2 ± 22.5 (3-112). Twenty-eight of 471 patients (5.9%) had NAB-cSTF at earliest after 3 and at latest after 103 treatment cycles. None of the 49 patients treated exclusively with incobotulinumtoxinA over 8.4 ± 4.2 (1-14) years developed NAB-cSTF. Independent risk factors for NAB-cSTF were high BoNT dose per treatment, switching between onabotulinumtoxinA and other BoNT formulations (except for switching to incobotulinumtoxinA), and treatment of neck muscles. CONCLUSIONS: We present a follow-up study with the longest duration to date on the incidence of NAB-cSTF in patients treated with various BoNT formulations, including incobotulinumtoxinA. Whereas the overall risk of NAB-cSTF is low across indications and BoNT formulations, our findings underpin the recommendations to use the lowest possible dose particularly in cervical dystonia, and to avoid unnecessary switching between different formulations.

来源:Neurology,查看原文。版权归原作者所有。

引用

  1. Walter U, Mühlenhoff C, Benecke R, et al. Frequency and risk factors of antibody-induced secondary failure of botulinum neurotoxin therapy. Neurology. 2020. PMID: 32332130. doi:10.1212/WNL.0000000000009444

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。